Caplyta Starting Dose for Bipolar Depression
The recommended starting dose of Caplyta (lumateperone) for bipolar depression is 42 mg once daily, with no dose titration required. 1
Dosing Specifications
According to the FDA-approved prescribing information, Caplyta should be initiated at 42 mg administered orally once daily with or without food 1. This is a critical distinction from many other psychiatric medications—dose titration is not required, meaning patients start at the therapeutic dose immediately 1.
Dosing Modifications
You need to adjust the dose in specific clinical scenarios:
Hepatic Impairment
- For moderate or severe hepatic impairment (Child-Pugh class B or C): reduce to 21 mg once daily 1
Drug Interactions
When patients are taking CYP3A4 inhibitors, dose reduction is mandatory:
- Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): reduce to 10.5 mg once daily 1
- Moderate CYP3A4 inhibitors (e.g., diltiazem, erythromycin): reduce to 21 mg once daily 1
Avoid concomitant use with CYP3A4 inducers entirely 1
Clinical Context
Caplyta is FDA-approved for depressive episodes associated with bipolar I or II disorder in adults, both as monotherapy and as adjunctive therapy with lithium or valproate 1. Recent meta-analyses confirm its efficacy, showing statistically significant improvements in MADRS scores compared to placebo 2, with lumateperone 42 mg demonstrating efficacy across a broad range of depressive symptoms 3.
Safety Monitoring
Begin monitoring within 1-2 weeks of initiation for suicidal thoughts and behaviors, as antidepressants (including atypical antipsychotics used for bipolar depression) carry this risk 1. The medication is generally well-tolerated with low extrapyramidal symptom risk and minimal metabolic effects 4.
Common Pitfalls to Avoid
- Do not titrate the dose upward from a lower starting point—42 mg is both the starting and maintenance dose for most patients
- Do not forget to reduce the dose when hepatic impairment or CYP3A4 inhibitor co-administration is present—this is mandatory, not optional
- Do not use in patients with known hypersensitivity to lumateperone (contraindicated) 1